ASH 2022 | Clinical utility of the homologous recombination deficiency score in AML & MDS
Rashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on a study that evaluated the clinical utility of the homologous recombination deficiency (HRD) score in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The study reported that patients with higher HRD scores had a higher likelihood of having a complex karyotype and TP53 mutations. In addition, a higher HRD score was associated with worse outcomes. The study suggests that patients with complex karyotypes and TP53 mutations could benefit from drugs targeting the HR pathway. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Physicians Education Resource: Speakers Bureau; Aptitude Health: Speakers Bureau; Novartis: Consultancy; Amgen: Consultancy.
